Valuation: SpringWorks Therapeutics, Inc.

Market Cap 354.06Cr 311.4Cr 289.29Cr 266.07Cr 498.96Cr 34TCr 507.91Cr 3.46TCr 1.35TCr 17TCr 1.33TCr 1.3TCr 58TCr P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 308.66Cr 271.47Cr 252.19Cr 231.95Cr 434.98Cr 30TCr 442.78Cr 3.02TCr 1.18TCr 15TCr 1.16TCr 1.13TCr 51TCr EV / Sales 2023
36,25,07,725x
EV / Sales 2024 1,16,54,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap.
01/07/25 Issuer sale

General Counsel

3,97,427 0.5304%
01/07/25 Issuer sale

Chief Technology Officer

3,69,000 0.4924%
01/07/25 Issuer sale

Director

1,03,482 0.1381%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+58.43% 354.06Cr
+1.54%-2.48%+16.87%-9.25% 6.63TCr
+1.07%+2.59%+37.23%+201.52% 5.26TCr
+10.08%+51.80%+51.80%+51.80% 4.33TCr
-1.32%-6.34%-56.98%-57.24% 3.86TCr
+0.76%-2.54%+51.42%-27.52% 2.96TCr
+1.01%-0.07%+66.22%+84.64% 2.33TCr
-4.24%-12.49%+59.07%-56.02% 2.26TCr
-1.21%-4.51%+2.22%+174.24% 2.02TCr
-0.22%-1.17%+61.61%+123.29% 1.63TCr
Average +0.77%-1.20%+28.95%+54.39% 3.16TCr
Weighted average by Cap. +1.48%-0.64%+27.08%+49.44%

Financials

2023 2024
Net sales 5.45 4.79 4.45 4.09 7.68 527.5 7.81 53.22 20.76 257.29 20.45 20.01 892.62 191.59 168.5 156.54 143.97 269.99 18.55T 274.83 1.87T 730.13 9.05T 719.26 703.71 31.4T
Net income -33Cr -29Cr -27Cr -24Cr -46Cr -3.15TCr -47Cr -317.64Cr -123.89Cr -1.54TCr -122.05Cr -119.41Cr -5.33TCr -26Cr -23Cr -21Cr -19Cr -36Cr -2.5TCr -37Cr -252.2Cr -98Cr -1.22TCr -97Cr -95Cr -4.23TCr
Net Debt -66Cr -58Cr -54Cr -49Cr -92Cr -6.35TCr -94Cr -640.47Cr -249.82Cr -3.1TCr -246.1Cr -240.78Cr -11TCr -45Cr -40Cr -37Cr -34Cr -64Cr -4.4TCr -65Cr -443.58Cr -173.02Cr -2.14TCr -170.44Cr -166.76Cr -7.44TCr
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock